Tanja Stadler, head of the Confederation’s scientific task force, believes that a vaccine for children under 12 should be available soon. The manufacturer Pfizer / Biontech presented preliminary data.
Sydney residents come out this Monday by nearly four months strict containment.
The World Health Organization estimates that between 10 and 20% of people develop lasting symptoms after infection with the coronavirus.
The cases of major depressive disorder and anxiety disorders increased by more than 25% in 2020 around the world due to the pandemic, according to a study.
■ The Vine of Nations attributed to the Vaccine Alliance
The vineyard of the Vine of Nations was symbolically handed over to GAVI, the Vaccine Alliance on Monday, by Serge Dal Busco, president of the Geneva Council of State. This recognition aims to honor the commitment of this organization to guarantee fair and equitable access to vaccines in all countries of the world.
From the start of the pandemic, GAVI developed and co-led Covax in collaboration with various partners, vaccine manufacturers from developed and developing countries as well as the World Bank. “This discount for the 2020 vintage is a great opportunity to recognize the key role of GAVI in the health center of international Geneva,” said Serge Dal Busco during the ceremony.
■ WHO recommends a third dose of vaccine for immunocompromised people
A WHO expert committee recommended Monday to give an additional dose of anti-Covid vaccine to people “moderately or severely immunocompromised”, for all vaccines approved by the UN agency. They were careful to explain that this was not about recommending a third dose for the general population, for which the organization continues to recommend a moratorium until the end of the year, to release doses. and give them to countries where the vaccination rate remains far too low.
“This third dose should be separated from the second by one to three months,” said Dr Kate O’Brien, director of the vaccination department at WHO. The same committee indicated that a third dose was needed for patients over the age of 60 who have been immunized with anti-Covid vaccines from Chinese companies Sinovac and Sinopharm. The third dose may be another vaccine of a different type.
■ Nez Rouge will not run in Neuchâtel during the holidays
Nez Rouge Neuchâtel will not be behind the wheel during the holiday season. The steering committee unanimously decided to cancel the operation for the 2nd consecutive year, so as not to have to require a covid certificate from all its volunteers. Discussions are however underway to possibly offer driving services to companies for their end-of-year supper.
■ The Erna Hamburger Prize awarded to vaccinologist Sarah Gilbert
Sarah Gilbert, Professor of Vaccinology at the Jenner Institute at Oxford University, is the recipient of the 2021 Erna Hamburger Prize awarded by EPFL. With her laboratory, she participated in the development of the AstraZeneca vaccine. Since the start of the year, honors and rewards have been raining down on this brilliant and discreet researcher. She became Lady Commander of the British Empire and there is even a Barbie in her image.
Read about it:
The Erna Hamburger Prize will be awarded to her on October 18. This distinction is awarded each year by the EPFL-WISH foundation (Women in Science and Humanities Foundation). It crowns an exemplary female career in science, in tribute to Erna Hamburger, the first woman to be appointed full professor at EPFL.
■ 60.5% of the population is fully vaccinated
From October 4 to October 10, 167,813 doses of the Covid-19 vaccine were administered in Switzerland. In total, 60.5% of the population is therefore fully vaccinated, according to data published Monday on the website of the Federal Office of Public Health (OFSP).
Since the start of the vaccination campaign, 10,711,332 doses of vaccine have been administered. And 5,230,500 people have received two doses of serum and 250,332 so far only one injection. On average, 23,973 vaccinations were performed per day. Compared to the previous week, the rate of injections has accelerated by 1%.
■ Switzerland has 2,262 new cases in three days
The main information from the latest bulletin from the Federal Office of Health (OFSP):
- Switzerland has 2262 additional cases of coronavirus on Monday in 72 hours;
- Eight additional deaths are deplored;
- 38 patients were hospitalized;
- During the last 72 hours, the results of 99,573 tests have been transmitted. The positivity rate is 2.27%.
- Over the last 14 days, the total number of infections is 13,771, or 159.3 new infections per 100,000 inhabitants.
- The reproduction rate, which has a delay of ten days, is 0.89.
- Covid-19 patients occupy 16.70% of available places in intensive care, with an occupancy rate of 72.60%.
■ The Kremlin is alarmed by mortality but excludes new measures
The Russian government has ruled “unacceptable” the low vaccination rate in Russia, the cause of “high” mortality, but has ruled out introducing health restrictions in order to preserve the economy.
Russia, the hardest hit country in Europe, is facing an acceleration of the epidemic, with nearly 1,000 dead and 30,000 new infections recorded in 24 hours on Monday. In addition to the low respect for barrier gestures, the spread of the virus is facilitated by the low vaccination rate – a little over 30% of Russians are fully vaccinated, according to the specialized site Gogov – against a background of public mistrust.
■ Merck files an authorization request for its pill in the USA
The American laboratory Merck announced Monday that it had filed an emergency authorization request with the United States Medicines Agency, the FDA, for its pill which, according to a clinical trial, reduces by two the risks of hospitalization and death of patients with Covid-19.
Read about it:
If approved, this drug called molnupiravir would represent a major breakthrough in the fight against the pandemic by making it possible to reduce severe forms of the disease quite easily. “The extreme consequences of this pandemic demand that we act with unprecedented urgency, and this is what our teams have done by submitting this request (for authorization) of molnupiravir to the FDA,” said Robert Davis, boss of the company, cited in the press release.
■ Canton of Bern concerned about the effectiveness of rapid antigenic tests
The reliability of rapid antigenic tests is causing concern among the Bernese health directorate, says the Bund. These tests would not meet the standards for obtaining a covid certificate, according to the words of the spokesperson for the cantonal health service, reported by the German newspaper.
The Zurich health service is also supporting the case, according to SRF. However, the Federal Office of Public Health says rapid antigenic tests are reliable if the test is carried out within four days of the onset of symptoms.
■ In New Zealand, unvaccinated caregivers will no longer be able to exercise
The country announced Monday that most caregivers will no longer be able to carry out their activity without receiving the vaccine against Covid-19. The same goes for teachers.
Doctors, nurses and other caregivers directly in contact with patients should be vaccinated before December 1. Education personnel in contact with students must have received two doses by January 1.
■ Sydney comes out of nearly four months of confinement
Sydney residents came out of nearly four months of strict containment on Monday, decreed in Australia’s largest city to block the epidemic. The restrictions lasted a total of 106 days.
They were lifted following the drop in new contaminations – 496 cases recorded on Monday in New South Wales – and thanks to the progress of vaccination, more than 70% of the population aged over 16 having received the two doses of the vaccine.
■ Positive results for an Astrazeneca drug
A cocktail of Astrazeneca antibodies gave results considered positive by the pharmaceutical company in phase 3 clinical trials. The trial of the drug AZD7442, a combination of antibodies, “produced a statistically satisfactory reduction in” cases. of serious Covid-19 or deaths due to the disease compared to a placebo in non-hospitalized patients with mild to moderate symptoms ”of Covid-19, details the Astrazeneca press release.
The clinical trial involved 903 participants, 90% of whom were from categories of patients deemed to be at high risk of developing severe forms. Astrazeneca has applied for authorization from the United States Drug Authority (FDA). The Swedish-British group announced in March an agreement with the United States to provide the country this year up to 700,000 doses of this treatment for a total amount of 726 million dollars.
■ Soon a vaccine for children under 12
The vaccine against Covid-19 for children under 12 should soon be marketed, believes the head of the Confederation’s scientific task force. Manufacturer Pfizer / Biontech presented preliminary data for children aged 5 to 11.
The data should soon be submitted to health authorities for approval, explains Tanja Stadler in an interview released on Monday by the German-speaking newspaper. view. While the virus is less dangerous for children than for the elderly, there are also severe forms of the disease in children and long covid, she adds.
“Children and their parents must have the choice of whether or not to be vaccinated”, declares this mother of two children, who will have them vaccinated as soon as there is an authorization and a recommendation from the Swissmedic supervisory authority.
■ Vaccines are 90% effective against severe forms according to a French study
Vaccination against Covid-19 reduces the risk of hospitalization and death by 90% in people over 50 and also seems effective against the Delta variant, on which we still lack perspective, according to a large French study alive actual published Monday.
“This means that vaccinated people have 9 times less risk of being hospitalized or dying from Covid-19 than unvaccinated people”, explains to AFP the epidemiologist Mahmoud Zureik, director of the Epi-Phare structure , which associates the Health Insurance (Cnam) and the Medicines Agency (ANSM).
To reach this conclusion, Epi-Phare researchers compared the data of 11 million vaccinated people over the age of 50 with those of 11 million unvaccinated people in the same age group, over a period of from December 27, 2020 (start of vaccination in France) to July 20. From the 14th day after the injection of the second dose, the researchers observed “a reduction in the risk of hospitalization greater than 90%”.